
About Godavaridrugs
Godavaridrugs is a publicly listed company based in Secunderabad (India) founded in 1987. CMO services for APIs, intermediates, and fine chemicals are offered. The company has 92 employees. Its Indian entity Godavari Drugs Limited reported revenue of βΉ107 Cr. Godavaridrugs offers products and services including APIs, Drug Intermediaries, and Fine Chemicals. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.
Company details
Godavari Drugs Limited is in the business of Contract Manufacturing, Loan License Manufacturing, Manufacturing and Supply of API, drug intermediaries and fine chemicals. Reaction capabilities include Chiral chemistry including resolutions, asymmetric inductions, racemisation and asymmetric transformation, Vapor phase catalytic reactions at high temperature like oxidation, reduction, amoxidation, etc., High pressure liquid phase reactions like hydrogenation, oxidation, etc., Selenium chemistry including selenium oxidation reactions, Continuous distillative reactions in packed columns like esterifications, Oxidation using nitric acid, Piperazine based reactions along with recovery of piperazine, Chlorination, Grignard reaction, Friedel-kraft reaction
- Headquarters Secunderabad, India
- Employees 92
- Stage Public
- SectorsHealthcare
- Website godavaridrugs.com
- Social LinkedIn
- Legal Name Godavari Drugs Limited
- Market Cap₹126 Cr
GODAVARI · BSE
- Share Price₹116.55
+0.56% today
- Revenue₹106 Cr
FY 2025-26 · -6.7% YoY
- EBITDA₹10.30 Cr
Margin 9.7%
- Net Profit₹3.65 Cr
FY 2025-26 · -15.7% YoY
- P/E (TTM)35.0x
P/B 1.7x
- ROE6.9%
ROCE 6.8%
- Debt / Equity1.23
Interest cover 50.6x
- Employee Count92
Associated legal entities of Godavaridrugs
Godavaridrugs operates through Godavari Drugs Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Godavari Drugs Limited Listed CIN L24230TG1987PLC008016 | Active | 02 Dec 1987 | Secunderabad, Telangana | ₹107 Cr | 92 | 8 | View details |
Products & Services of Godavaridrugs
Godavaridrugs offers a comprehensive portfolio of products and services, including APIs, Drug Intermediaries, and Fine Chemicals.
Active ingredients for pharmaceutical manufacturing and supply
Components used in drug production for global markets
High-purity chemicals for life science applications
Board of directors of Godavari Drugs Limited (Godavaridrugs)
Godavari Drugs Limited is the primary company behind Godavaridrugs. The board of Godavari Drugs Limited currently have 6 directors; the longest-serving is Mukund Kakani, appointed in 1987. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mukund Kakani DIN 00104646 | Managing Director | 03 Dec 1987 | 38 yrs 11 mo | Godavari Drugs Limited |
| Ghanshyam Jaju DIN 00104601 | Director | 03 Dec 1987 | 38 yrs 11 mo | Godavari Drugs Limited |
| Mohit Jaju DIN 03405414 | Whole-time director | 10 May 2012 | 14 yrs 6 mo | Godavari Drugs Limited |
| Mahendra Uday Bhalerao DIN 01876185 | Director | 12 Nov 2022 | 4 yrs | Godavari Drugs Limited |
| Dinesh Udpa DIN 10503106 | Director | 13 Feb 2024 | 2 yrs 9 mo | Godavari Drugs Limited |
| Shilpa Bung DIN 08257931 | Director | 29 May 2025 | 1 yr 5 mo | Godavari Drugs Limited |
IPO & Listings of Godavaridrugs
Godavaridrugs is a publicly listed company on the BSE with ticker symbol GODAVARI in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Jun 1995
- Listed onBSE: 530317
- Listed entityGodavari Drugs Limited
- Exchange sectorHealth technology
- ISININE362C01012
- Share price₹131.55 (+0.04% on the day) · 2026-10-14
- Market capitalisation₹133 Cr
- Price to earnings28.0
- EPS (diluted, trailing year)₹4.70
- Volume (last session)5,219
Financials of Godavaridrugs
Exchange-reported figures of Godavari Drugs Limited, the listed company behind Godavaridrugs (BSE: GODAVARI).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 106 | 113 | 157 | 160 | 161 | 123 | 95.70 |
| Revenue growth | -6.7% | -27.7% | -1.8% | -0.9% | +31.3% | +28.2% | - |
| EBITDA | 10.30 | 11.82 | 13.22 | 9.92 | 11.30 | 9.83 | 6.03 |
| EBITDA margin | +9.7% | +10.4% | +8.4% | +6.2% | +7.0% | +8.0% | +6.3% |
| Profit before tax | 5.05 | 5.62 | 6.93 | 4.93 | 7.03 | 5.70 | 2.29 |
| Net profit | 3.65 | 4.33 | 5.62 | 3.60 | 5.25 | 4.12 | 2.00 |
| Net profit margin | +3.5% | +3.8% | +3.6% | +2.3% | +3.3% | +3.4% | +2.1% |
| EPS (βΉ) | 4.04 | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | 2.66 |
| Balance sheet | |||||||
| Total assets | 158 | 109 | 97.49 | 69.98 | 53.43 | 55.63 | 48.53 |
| Net worth | 75.80 | 43.35 | 38.97 | 33.42 | 29.63 | 24.39 | 20.26 |
| Total debt | 81.94 | 64.35 | 57.77 | 35.85 | 23.07 | 30.46 | 27.60 |
| Cash & bank | 14.51 | 2.37 | 2.62 | 3.08 | 2.28 | 1.64 | 1.43 |
| Net working capital | 71.61 | 46.11 | 53.06 | 37.19 | 27.86 | 33.07 | 26.01 |
| Cash flow | |||||||
| Cash from operations | 0.73 | 11.20 | 18.41 | 13.22 | 11.23 | 1.33 | 6.24 |
| Cash from investing | (25.95) | (19.51) | (13.22) | (8.64) | (4.97) | (1.25) | (6.68) |
| Cash from financing | 37.35 | 8.07 | (5.65) | (3.77) | (5.62) | 0.13 | 0.34 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 28.23 | 27.96 | 33.16 | 22.18 | 26.65 | 23.81 | 25.50 | 29.55 |
| Revenue growth (YoY) | +5.9% | +17.4% | +30.0% | -24.9% | +2.2% | -26.1% | - | - |
| Other income | (0.12) | 0.15 | 0.25 | 0.27 | 0.64 | 0.01 | 0.11 | 0.10 |
| Total expenses | 25.43 | 25.44 | 30.22 | 19.71 | 24.65 | 20.91 | 22.39 | 26.97 |
| EBITDA | 2.80 | 2.52 | 2.94 | 2.47 | 2.00 | 2.90 | 3.11 | 2.58 |
| EBITDA margin | +9.9% | +9.0% | +8.9% | +11.1% | +7.5% | +12.2% | +12.2% | +8.7% |
| Depreciation | 0.61 | 0.59 | 0.61 | 0.61 | 0.60 | 0.60 | 0.67 | 0.64 |
| Interest | 0.84 | 0.90 | 0.96 | 1.11 | 0.91 | 1.00 | 1.11 | 1.11 |
| Profit before tax | 1.23 | 1.18 | 1.62 | 1.02 | 1.13 | 1.31 | 1.44 | 0.93 |
| Tax | 0.27 | 0.07 | 0.33 | 0.26 | 0.12 | 0.26 | 0.55 | 0.15 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 28.23 | 27.96 | 33.16 | 22.18 | 26.65 | 23.81 | 25.50 | 29.55 |
| Revenue growth (YoY) | +5.9% | +17.4% | +30.0% | -24.9% | +2.2% | -26.1% | - | - |
| Other income | (0.12) | 0.15 | 0.25 | 0.27 | 0.64 | 0.01 | 0.11 | 0.10 |
| Total expenses | 25.43 | 25.44 | 30.22 | 19.71 | 24.65 | 20.91 | 22.39 | 26.97 |
| EBITDA | 2.80 | 2.52 | 2.94 | 2.47 | 2.00 | 2.90 | 3.11 | 2.58 |
| EBITDA margin | +9.9% | +9.0% | +8.9% | +11.1% | +7.5% | +12.2% | +12.2% | +8.7% |
| Depreciation | 0.61 | 0.59 | 0.61 | 0.61 | 0.60 | 0.60 | 0.67 | 0.64 |
| Interest | 0.84 | 0.90 | 0.96 | 1.11 | 0.91 | 1.00 | 1.11 | 1.11 |
| Profit before tax | 1.23 | 1.18 | 1.62 | 1.02 | 1.13 | 1.31 | 1.44 | 0.93 |
| Tax | 0.27 | 0.07 | 0.33 | 0.26 | 0.12 | 0.26 | 0.55 | 0.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 106 | 113 | 157 | 160 | 161 | 123 | 95.70 |
| Revenue growth | -6.7% | -27.7% | -1.8% | -0.9% | +31.3% | +28.2% | - |
| Other income | 1.16 | 0.98 | 0.62 | 0.88 | 0.28 | 0.41 | 0.33 |
| Total expenses | 95.51 | 102 | 143 | 150 | 150 | 113 | 89.67 |
| Employee cost | 5.70 | 5.03 | 5.13 | 4.84 | 4.96 | 3.94 | 3.45 |
| EBITDA | 10.30 | 11.82 | 13.22 | 9.92 | 11.30 | 9.83 | 6.03 |
| EBITDA margin | +9.7% | +10.4% | +8.4% | +6.2% | +7.0% | +8.0% | +6.3% |
| Depreciation | 2.43 | 2.45 | 1.99 | 1.94 | 1.70 | 1.22 | 1.16 |
| Interest | 3.98 | 4.73 | 4.92 | 3.93 | 2.85 | 3.32 | 2.91 |
| Profit before tax | 5.05 | 5.62 | 6.93 | 4.93 | 7.03 | 5.70 | 2.29 |
| Tax | 0.97 | 1.25 | 1.38 | 1.15 | 1.78 | 1.58 | 0.29 |
| Net profit | 3.65 | 4.33 | 5.62 | 3.60 | 5.25 | 4.12 | 2.00 |
| Net profit margin | +3.5% | +3.8% | +3.6% | +2.3% | +3.3% | +3.4% | +2.1% |
| EPS (βΉ) | 4.04 | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | 2.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.13 | 7.53 | 7.53 | 7.53 | 7.53 | 7.53 | 7.53 |
| Reserves & surplus | 60.42 | 35.82 | 31.44 | 25.89 | 22.10 | 16.86 | 12.73 |
| Shareholders' funds (net worth) | 75.80 | 43.35 | 38.97 | 33.42 | 29.63 | 24.39 | 20.26 |
| Secured loans | 60.36 | 49.86 | 47.77 | 10.61 | 5.10 | 7.23 | 19.57 |
| Unsecured loans | 21.58 | 14.49 | 10.00 | 25.24 | 17.97 | 23.23 | 8.03 |
| Total debt | 81.94 | 64.35 | 57.77 | 35.85 | 23.07 | 30.46 | 27.60 |
| Total liabilities | 158 | 109 | 97.49 | 69.98 | 53.43 | 55.63 | 48.53 |
| Assets | |||||||
| Gross block | 49.49 | 49.43 | 46.88 | 46.28 | 49.57 | 44.05 | 34.21 |
| Net block | 30.31 | 32.61 | 26.69 | 24.91 | 26.25 | 22.43 | 13.81 |
| Capital work in progress | 56.54 | 29.95 | 18.32 | 9.08 | 0.49 | 0.76 | 8.93 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 46.06 | 27.94 | 20.65 | 19.86 | 10.03 | 14.65 | 17.75 |
| Sundry debtors | 43.58 | 42.32 | 59.42 | 57.93 | 55.58 | 45.12 | 36.02 |
| Cash & bank balances | 14.51 | 2.37 | 2.62 | 3.08 | 2.28 | 1.64 | 1.43 |
| Loans & advances | 7.64 | 6.12 | 5.78 | 6.13 | 6.45 | 6.20 | 5.63 |
| Total current assets | 112 | 78.75 | 88.47 | 87.00 | 74.34 | 67.61 | 60.83 |
| Total current liabilities | 40.18 | 32.64 | 35.41 | 49.81 | 46.48 | 34.54 | 34.82 |
| Net working capital | 71.61 | 46.11 | 53.06 | 37.19 | 27.86 | 33.07 | 26.01 |
| Total assets | 158 | 109 | 97.49 | 69.98 | 53.43 | 55.63 | 48.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.37 | 2.62 | 3.08 | 2.28 | 1.64 | 1.43 | 1.53 |
| Net cash from operating activities | 0.73 | 11.20 | 18.41 | 13.22 | 11.23 | 1.33 | 6.24 |
| Net cash from investing activities | (25.95) | (19.51) | (13.22) | (8.64) | (4.97) | (1.25) | (6.68) |
| Net cash from financing activities | 37.35 | 8.07 | (5.65) | (3.77) | (5.62) | 0.13 | 0.34 |
| Net change in cash | 12.14 | (0.25) | (0.46) | 0.81 | 0.64 | 0.21 | (0.10) |
| Closing cash | 14.51 | 2.37 | 2.62 | 3.08 | 2.28 | 1.64 | 1.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -6.7% | -27.7% | -1.8% | -0.9% | +31.3% | +28.2% | - |
| EBITDA growth | -12.9% | -10.6% | +33.3% | -12.2% | +15.0% | +63.0% | - |
| PBT growth | -10.1% | -18.9% | +40.6% | -29.9% | +23.3% | +148.9% | +31.6% |
| Net income growth | -15.7% | -23.0% | +56.1% | -31.4% | +27.4% | +106.0% | - |
| Revenue CAGR (3Y) | -12.8% | -11.1% | +8.5% | +18.6% | +24.5% | +23.9% | +8.2% |
| EBITDA CAGR (3Y) | +1.3% | +1.5% | +10.4% | +18.1% | +27.3% | +34.5% | +4.9% |
| Profitability & leverage | |||||||
| Net income margin | +3.9% | +3.9% | +3.5% | +2.4% | +3.3% | +3.4% | +2.1% |
| Return on capital employed | +6.8% | +10.1% | +14.1% | +14.4% | +18.1% | +17.3% | +11.6% |
| Return on net worth | +6.9% | +10.6% | +15.3% | +12.0% | +19.4% | +18.5% | +10.2% |
| Debt / equity | 1.23 | 1.48 | 1.29 | 0.93 | 0.99 | 1.30 | 1.29 |
| Long-term debt / equity | 0.49 | 0.38 | 0.29 | 0.38 | 0.49 | 0.57 | 0.50 |
| Interest cover | 50.57 | 50.48 | 43.81 | 49.25 | 29.69 | 38.56 | 59.75 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.14 | 2.35 | 3.36 | 3.33 | 3.44 | 3.13 | 2.80 |
| Inventory turnover | 2.86 | 4.67 | 7.74 | 10.68 | 13.06 | 7.57 | 5.59 |
| Debtors turnover | 2.46 | 2.23 | 2.67 | 2.81 | 3.20 | 3.02 | 2.74 |
| EPS (βΉ) | 4.04 | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | 2.66 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 69.66 | 57.56 | 51.74 | 44.38 | 39.35 | 32.38 | 26.90 |
Similar companies to Godavaridrugs
Godavaridrugs has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed similar companies of Godavaridrugs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Godavaridrugs
Websites that share an audience with Godavaridrugs (godavaridrugs.com).
Websites whose visitors overlap most with Godavaridrugs. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Godavaridrugs (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Godavaridrugs
Complete news archive for Godavaridrugs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Godavaridrugs
Godavaridrugs was founded in 1987.
Godavaridrugs is headquartered in Secunderabad, India. It is registered at Secunderabad, Telangana, India.
Godavaridrugs has 92 employees.
The primary company behind Godavaridrugs, Godavari Drugs Limited, reported revenue of βΉ107 Cr for FY 2026, down 7% year on year.
Godavari Drugs Limited is in the business of Contract Manufacturing, Loan License Manufacturing, Manufacturing and Supply of API, drug intermediaries and fine chemicals. Reaction capabilities include Chiral chemistry including resolutions, asymmetric inductions, racemisation and asymmetric transformation, Vapor phase catalytic reactions at high temperature like oxidation, reduction, amoxidation, etc., High pressure liquid phase reactions like hydrogenation, oxidation, etc., Selenium chemistry including selenium oxidation reactions, Continuous distillative reactions in packed columns like esterifications, Oxidation using nitric acid, Piperazine based reactions along with recovery of piperazine, Chlorination, Grignard reaction, Friedel-kraft reaction.
Godavaridrugs's top competitors include Laurus Labs, Symbiotec and SeQuent.
Godavaridrugs offers APIs, Drug Intermediaries, and Fine Chemicals.
Yes, Godavaridrugs is publicly traded on BSE under the ticker symbol GODAVARI.
Godavaridrugs operates through Godavari Drugs Limited.
The legal entities of Godavaridrugs currently have 7 directors, including Mohit Jaju, Mukund Kakani, Ghanshyam Jaju and others.
